For eleven years, a boy born in Morocco lived in a silence not chosen but inherited — the consequence of a genetic mutation that closed him off from the auditory world before he ever entered it. At a hospital in Spain, doctors did not work around that silence with devices or surgery, but reached into its cause, correcting the genetic instruction that had written deafness into his biology. Aissam Dam can now hear, and in that single fact rests a question that will reshape medicine: if the root of hereditary deafness can be rewritten, how many other silences might be answered?
Gene therapy restores hearing to deaf Moroccan youth after 11 years of silence
Cobertura Relacionada
Usuarios de fármacos GLP-1 como Ozempic reportan anhedonia, un efecto secundario que les impide disfrutar de actividades…
CNN en Español · Aug 22 Moderna y Merck logran avance decisivo con vacuna personalizada contra el cáncerMerck y Moderna reportan éxito de una vacuna personalizada contra el melanoma que entrena el sistema inmunológico para a…
El Divisadero · Aug 21 Hepatitis virales: herramientas de prevención y cura al alcance en AysénGastroenterólogo del Hospital Regional Coyhaique explica las hepatitis virales, sus formas de transmisión y las herramie…
radiosantamaria.cl · Aug 21 Escuela España suspende clases por brote de enfermedades respiratorias en CoyhaiqueLa Escuela Diferencial España de Coyhaique suspendió clases por 48 horas tras confirmarse un brote de enfermedades respi…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
Gene therapy breakthrough in Morocco demonstrates medical advancement but lacks direct geopolitical implications; primarily a healthcare innovation story.
No significant power shifts. Spain's medical infrastructure gains soft power through healthcare innovation leadership in Mediterranean region.
Lente Econômica
Gene therapy breakthrough for hereditary deafness offers new non-invasive treatment pathway, potentially creating significant market opportunity in genetic medicine and audiology sectors.
Patients with hereditary hearing loss gain access to non-surgical treatment alternative to cochlear implants, potentially reducing healthcare costs and improving quality of life. May increase demand for genetic testing and early diagnosis services.
Regulatory bodies (EMA, FDA) will need to establish approval pathways for gene therapies targeting hereditary deafness. Healthcare systems may need to evaluate coverage and reimbursement policies. Potential for increased funding in genetic research and rare disease treatment programs.